Japan
Japan Proteomics Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Japan · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
China at $2.90 Bn.
India at 15.2% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$4.75 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.21 Bn | — | — |
| 2025 (base) | $2.49 Bn | +$278.3 Mn | — |
| 2026 (forecast) | $2.80 Bn | +$313.4 Mn | +12.6% |
| 2027 (forecast) | $3.15 Bn | +$352.8 Mn | +26.8% |
| 2028 (forecast) | $3.55 Bn | +$397.3 Mn | +42.8% |
| 2029 (forecast) | $4.00 Bn | +$447.4 Mn | +60.8% |
| 2030 (forecast) | $4.50 Bn | +$503.7 Mn | +81% |
| 2031 (forecast) | $5.07 Bn | +$567.2 Mn | +103.8% |
| 2032 (forecast) | $5.71 Bn | +$638.7 Mn | +129.5% |
| 2033 (forecast) | $6.43 Bn | +$719.1 Mn | +158.4% |
| 2034 (forecast) | $7.24 Bn | +$809.7 Mn | +191% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$15.59 Bn
Canada
$3.37 Bn
China
$2.90 Bn
Japan (this report)
$2.49 Bn
Germany
$1.19 Bn
UK
$972.2 Mn
Italy
$916.4 Mn
Brazil
$937.0 Mn
France
$883.9 Mn
India
$763.1 Mn
Spain
$664.0 Mn
Mexico
$647.0 Mn
Ecuador
$651.2 Mn
Saudi Arabia
$627.6 Mn
Australia
$520.9 Mn
Russia
$419.2 Mn
New Zealand
$415.1 Mn
South Africa
$284.6 Mn
UAE
$185.1 Mn
Egypt
$115.1 Mn
Philippines
$81.6 Mn
Malaysia
$61.0 Mn
Hong Kong
$58.9 Mn
Thailand
$48.9 Mn
Singapore
$42.5 Mn
Kenya
$28.7 Mn
Proteomics measures thousands of proteins in blood and tissue to find disease markers and new drug targets.
Key segments of the proteomics market include product (Instruments, Reagents and Services) and application (Drug Discovery, Clinical Diagnostics and Biomarker Research).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the proteomics market.
Routine use of genomics in screening, pharmacy and primary care gives the proteomics market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the proteomics market.
The proteomics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for proteomics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.
What doctors and scientists are doing in Proteomics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Japan · 3 shared keywords
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 1 shared keyword
Japan · 1 shared keyword
Digital Health · Japan
Healthcare Services · Japan
Healthcare Services · Japan
Medical Devices · Japan
Digital Health · Japan
Medical Devices · Japan